神経バイオマーカー市場：タイプ、用途、エンドユーザー別-2025～2030年の世界予測

神経バイオマーカー市場は、2023年に89億8,000万米ドルと評価され、2024年には102億4,000万米ドルに達すると予測され、CAGR 14.05％で成長し、2030年には225億6,000万米ドルに達すると予測されています。

神経バイオマーカー、中枢神経系に関連する生物学的状態の測定可能な指標は、神経疾患の診断と管理において極めて重要なツールとして浮上してきました。バイオマーカーの定義が広がるにつれ、脳の機能や構造の変化を示す遺伝子マーカー、タンパク質、画像所見などが含まれるようになりました。その必要性は、アルツハイマー病、パーキンソン病、多発性硬化症などの神経疾患の有病率が増加していることからも明らかであり、早期かつ正確な診断が患者の予後を著しく改善します。これらのバイオマーカーは、医薬品開発、疾患進行のモニタリング、治療戦略のカスタマイズなどに応用されており、最終用途は研究機関、医療施設、製薬会社などに及んでいます。市場成長の主要原動力は、神経疾患の罹患率の上昇、バイオマーカー技術の進歩、研究資金の増加です。主要ビジネス機会は、非侵襲的バイオマーカーの開発と、診断精度を高めるための人工知能との統合にあります。神経疾患に対するリキッドバイオプシーや、ゲノミクスとプロテオミクスの融合といったセグメントではイノベーションが重要です。しかし、市場開拓の妨げとなっているのは、規制の複雑さ、研究開発の高コスト、新規バイオマーカー候補の臨床検証の限界といった課題です。さらに、バイオマーカー研究の倫理的意味合いや患者のプライバシーに関する懸念が大きな障壁となっています。これらを克服するために、利害関係者は規制経路の合理化、官民協力の促進、倫理的ガイドラインと患者データ保護の提唱に焦点を当てるべきです。神経バイオマーカー市場の性質はダイナミックで学際的であり、神経科学者、バイオテクノロジスト、医療専門家による相乗的アプローチが要求されます。持続的な事業成長のためには、企業はしっかりとした研究開発に投資し、学術研究機関との共同研究の機会を探り、医療インフラが改善しつつある新興市場を対象にする必要があります。これらの戦略を取り入れることで、競合を強化し、神経バイオマーカーが世界の医療に与える影響を拡大することができます。

市場力学：急速に進化する神経バイオマーカー市場の主要市場洞察を公開

神経バイオマーカー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 神経疾患の有病率の増加
  • 費用対効果が高く、非侵襲的な診断システムへの需要
  • 早期診断と予防治療に対する嗜好の高まり
• 市場抑制要因
  • 政府による厳しい承認規制
• 市場機会
  • バイオマーカーの進歩に向けた研究開発への注目の高まり
  • シングルセルバイオセンサーの台頭
  • 発展途上国における低コストの臨床検査の増加
• 市場課題
  • 神経疾患の倫理的問題と受容の問題

ポーターのファイブフォース：神経バイオマーカー市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経バイオマーカー市場における外部からの影響の把握

外部マクロ環境要因は、神経バイオマーカー市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：神経バイオマーカー市場における競合情勢の把握

神経バイオマーカー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：神経バイオマーカー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経バイオマーカー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：神経バイオマーカー市場における成功への道筋を描く

神経バイオマーカー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 神経疾患の増加
    • 費用対効果が高く非侵襲的な診断システムの需要
    • 早期診断と予防治療への関心が高まる
  • 抑制要因
    • 承認に関する厳格な政府規制
  • 機会
    • バイオマーカーの進歩に向けた研究開発の重点の拡大
    • 新たな単一細胞バイオセンサー
    • 新興諸国における低コスト臨床検査の増加
  • 課題
    • 神経疾患の倫理的問題と受容の問題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 神経バイオマーカー市場：タイプ別

• イントロダクション
• ゲノム
• イメージング
• メタボロミクス
• プロテオーム

第7章 神経バイオマーカー市場：用途別

• イントロダクション
• アルツハイマー病
• 自閉症スペクトラム障害
• 多発性硬化症
• パーキンソン病

第8章 神経バイオマーカー市場：エンドユーザー別

• イントロダクション
• 病院の検査室
• 独立系臨床診断センター
• 研究機関

第9章 南北アメリカの神経バイオマーカー市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の神経バイオマーカー市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの神経バイオマーカー市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Acumen Pharmaceuticals, Inc
• Alseres Pharmaceuticals, Inc.
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Imagilys
• inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc.
• IXICO PLC
• Merck KGaA
• Proteome Sciences PLC
• QIAGEN GmbH
• Quanterix Corporation
• Quest Diagnostics Incorporated
• Rules-Based Medicine by Q2 Solutions
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. NEUROLOGICAL BIOMARKERS MARKET RESEARCH PROCESS
• FIGURE 2. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEUROLOGICAL BIOMARKERS MARKET DYNAMICS
• TABLE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

The Neurological Biomarkers Market was valued at USD 8.98 billion in 2023, expected to reach USD 10.24 billion in 2024, and is projected to grow at a CAGR of 14.05%, to USD 22.56 billion by 2030.

Neurological biomarkers, measurable indicators of a biological condition related to the central nervous system, have emerged as crucial tools in diagnosing and managing neurological diseases. As their definition broadens, these biomarkers include genetic markers, proteins, and imaging findings that signal changes in brain function or structure. Their necessity is underscored by the increasing prevalence of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis, where early and accurate diagnosis can significantly improve patient outcomes. These biomarkers find application in drug development, monitoring disease progression, and customizing therapeutic strategies, with end-use spanning research institutions, healthcare facilities, and pharmaceutical companies. Market growth is primarily driven by the rising incidence of neurological conditions, advancements in biomarker technology, and increased research funding. Key opportunities lie in the development of non-invasive biomarkers and integration with artificial intelligence to enhance diagnostic precision. Innovation is critical in areas like liquid biopsy for neurological conditions and the convergence of genomics and proteomics. However, market growth is hindered by challenges such as regulatory complexities, high costs of research and development, and limited clinical validation of new biomarker candidates. Additionally, the ethical implications of biomarker research and patient privacy concerns pose significant barriers. To overcome these, stakeholders should focus on streamlining regulatory pathways, fostering public-private collaborations, and advocating for ethical guidelines and patient data protection. The nature of the neurological biomarkers market is dynamic and interdisciplinary, demanding a synergistic approach among neuroscientists, biotechnologists, and healthcare professionals. For sustained business growth, companies should invest in robust R&D, explore collaboration opportunities with academic and research institutions, and target emerging markets where healthcare infrastructure is improving. Embracing these strategies will enhance competitiveness and expand the impact of neurological biomarkers on global healthcare.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neurological Biomarkers Market

The Neurological Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of neurological disorders
  • Demand for cost-effective and non-invasive diagnostic system
  • Increasing preferences on early diagnosis & preventive treatment
• Market Restraints
  • Stringent government regulations for approvals
• Market Opportunities
  • Growing R&D focus for advancements in biomarkers
  • Emerging single-cell biosensors
  • Growth of low-cost clinical trials in developing countries
• Market Challenges
  • Ethical problems and acceptance issues of neurological disorders

Porter's Five Forces: A Strategic Tool for Navigating the Neurological Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neurological Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neurological Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neurological Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neurological Biomarkers Market

A detailed market share analysis in the Neurological Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neurological Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neurological Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neurological Biomarkers Market

A strategic analysis of the Neurological Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neurological Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acumen Pharmaceuticals, Inc, Alseres Pharmaceuticals, Inc., Bio-Rad Laboratories, Inc., bioMerieux SA, Imagilys, inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc., IXICO PLC, Merck KGaA, Proteome Sciences PLC, QIAGEN GmbH, Quanterix Corporation, Quest Diagnostics Incorporated, Rules-Based Medicine by Q2 Solutions, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Neurological Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Genomic, Imaging, Metabolomic, and Proteomic.
• Based on Application, market is studied across Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Parkinson's Disease.
• Based on End-user, market is studied across Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of neurological disorders
    • 5.1.1.2. Demand for cost-effective and non-invasive diagnostic system
    • 5.1.1.3. Increasing preferences on early diagnosis & preventive treatment
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent government regulations for approvals
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing R&D focus for advancements in biomarkers
    • 5.1.3.2. Emerging single-cell biosensors
    • 5.1.3.3. Growth of low-cost clinical trials in developing countries
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical problems and acceptance issues of neurological disorders
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neurological Biomarkers Market, by Type

• 6.1. Introduction
• 6.2. Genomic
• 6.3. Imaging
• 6.4. Metabolomic
• 6.5. Proteomic

7. Neurological Biomarkers Market, by Application

• 7.1. Introduction
• 7.2. Alzheimer's Disease
• 7.3. Autism Spectrum Disorders
• 7.4. Multiple Sclerosis
• 7.5. Parkinson's Disease

8. Neurological Biomarkers Market, by End-user

• 8.1. Introduction
• 8.2. Hospital Laboratories
• 8.3. Independent Clinical Diagnostic Centers
• 8.4. Research Organizations

9. Americas Neurological Biomarkers Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Neurological Biomarkers Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Neurological Biomarkers Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Acumen Pharmaceuticals, Inc
• 3. Alseres Pharmaceuticals, Inc.
• 4. Bio-Rad Laboratories, Inc.
• 5. bioMerieux SA
• 6. Imagilys
• 7. inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc.
• 8. IXICO PLC
• 9. Merck KGaA
• 10. Proteome Sciences PLC
• 11. QIAGEN GmbH
• 12. Quanterix Corporation
• 13. Quest Diagnostics Incorporated
• 14. Rules-Based Medicine by Q2 Solutions
• 15. Thermo Fisher Scientific Inc.